Udvidelsesundersøgelse for at evaluere, hvor sikker og tolerabel NBI-921352 er som en supplerende terapi for forsøgspersoner med SCN8A-DEE
En prospektiv, langsigtet, interventionel, aktiv forlængelsesundersøgelse til evaluering af sikkerheden og tolerabiliteten af NBI-921352 som supplerende terapi hos personer med SCN8A udviklingsmæssigt og epileptisk encefalopatisyndrom (SCN8A-DEE)
Extension study to evaluate how safe and tolerable the drug NBI-921352 is when used as adjunctive therapy in participants with SCN8A developmental and epileptic encephalopathy syndrome (SCN8A-DEE).
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
California
-
San Francisco, California, Forenede Stater, 94143
- UCSF Medical Center
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20010
- Children's National Hospital
-
-
New York
-
Rochester, New York, Forenede Stater, 14642
- University of Rochester
-
-
Texas
-
Fort Worth, Texas, Forenede Stater, 76104
- Cook Children's Medical Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria:
For Participants Who Participated in NBI-921352-DEE2012:
- Written or oral pediatric assent from the participant and written informed consent from the participant's parent(s) or legal guardian(s) for pediatric participants and adult participants who are not capable of providing consent. Adult participant who are ≥18 years of age and capable of providing consent should sign an Informed Consent Form (ICF).
- Completed 16 weeks of treatment in Study NBI-921352-DEE2012.
- Continue to use a nocturnal alerting system or practice consistent with standards of care for the duration of the study.
- Have an adequate rescue medication regimen per the investigator's judgment in place for the duration of the study.
For Participants Who did not Participate in NBI-921352-DEE2012:
- Written or oral pediatric assent from the participant if deemed capable of providing assent and written informed consent from the participant's parent(s) or legal guardian(s) for pediatric participants and for adult participants who are not capable of providing consent. Adult participants who are capable of providing consent should sign an ICF.
- Be a male or female 2 to 21 years of age, inclusive.
- Have a diagnosis of SCN8A-DEE supported by both clinical and genetic findings.
- Have on average at least 1 countable motor seizure per week and not be seizure-free for more than 20 consecutive days.
- Being treated with at least 1 other antiseizure medication (ASM), but no more than 4 ASMs.
- Have failed to achieve seizure freedom with at least 2 ASMs.
- Have a body weight of at least 10 kilograms.
Key Exclusion Criteria
For Participants Who Participated in NBI-921352-DEE2012:
- Have developed any other disorder for which the treatment takes priority over treatment of SCN8A-DEE or is likely to interfere with study treatment or impair treatment compliance.
For Participants Who did not Participate in NBI-921352-DEE2012:
- Have symptoms that would be more consistent with another epilepsy disorder such as Dravet syndrome (for example, fever-induced episodes of status epilepticus, frequent myoclonic seizures, worsening on sodium channel blockers, absence seizures with generalized spike-and-wave electroencephalogram [EEG] as the sole seizure type).
- Currently receiving cannabinoids or medical marijuana except Epidiolex/Epidyolex, unless approved by the Sponsor.
- Currently taking systemic steroids (excluding inhaled medication for asthma treatments and intranasal steroids for allergies) such as adrenocorticotropin hormone, high-dose prednisolone for epileptic spasms. If participant has received these medications in the past, they must be off these medications for at least 3 months prior to the screening visit and these drugs may not be initiated during the duration of the study. Intermittent steroids to treat non-epilepsy-related diseases (such as allergies or dermatological conditions) are not exclusionary.
- Have a history of moderate or severe head trauma or other neurological disorders or systemic medical diseases that are, in the investigator's opinion, likely to affect nervous system functioning.
- Have a clinically significant medical condition or chronic disease, that in the opinion of the investigator would preclude the participant from participating in and completing the study or that could confound interpretation of study outcome.
- Have clinically significant abnormal vital signs at the screening visit, as determined by the investigator.
- Have one or more clinical laboratory test values outside the reference range, based on blood samples taken at the screening visit, that are of potential risk to the participants safety as determined by the investigator.
- Have, at the screening visit, an electrocardiogram (ECG) finding of a corrected QT interval using Fridericia's formula (QTcF) > 450 milliseconds (msec) or presence of any significant cardiac abnormality.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: NBI-921352
NBI-921352 administered for up to 164 weeks. |
Administered orally |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Number of Participants with Serious treatment-emergent adverse events (TEAEs), TEAEs Leading to Discontinuation and Fatal TEAEs
Tidsramme: Day 1 to Week 168
|
Day 1 to Week 168
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Percentage Change from Baseline in 28-day Seizure Frequency for Countable Motor Seizures
Tidsramme: Baseline, up to Week 162
|
Baseline, up to Week 162
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Clinical Development Lead, Neurocrine Biosciences
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- NBI-921352-DEE2013
- 2021-004393-62 (EudraCT nummer)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .